Table 2.
Clinical characteristics of patients from whom sera were used for miRNA profiling studies
| Characteristic | NSCD group | SCD group | P value |
|---|---|---|---|
| Number of patients | 29 | 13 | |
| Gender (%) | |||
| M | 13 (44.8) | 8 (61.5) | 0.323 |
| F | 16 (55.2) | 5 (38.5) | 0.354 |
| Median age (IQR) (y) | 32 (17) | 45 (28.5) | 0.053 |
| Median disease duration (IQR) (y) | 4 (6.1) | 11 (12.3) | 0.24 |
| Disease location (%) | |||
| Ileal | 14 (48.3) | 6 (46.2) | 0.901 |
| Colonic | 3 (10.3) | 1 (7.6) | 0.785 |
| Ileocolonic | 12 (41.4) | 6 (46.2) | 0.774 |
| Upper GI | 0 (0.0) | 0 (0.0) | 1.000 |
| Disease behaviour (%) | |||
| Inflammatory | 16 (55.2) | 0 (0.0) | 0.001 |
| Stricturing | 0 (0.0) | 13 (100.0) | <0.001 |
| Penetrating | 13 (44.8) | 0 (0.0) | 0.004 |
| Median CDAI score (IQR) | 135.5 (135.5) | 135 (136.5) | 0.59 |
| Smoking status (%) | |||
| Current | 6 (20.7) | 6 (46.2) | 0.095 |
| Previous | 2 (6.9) | 2 (15.4) | 0.392 |
| Never | 6 (20.7) | 1 (7.6) | 0.298 |
| Unknown | 15 (51.7) | 4 (30.8) | 0.214 |
| Stricture present (%) | |||
| Yes | 0 (0.0) | 11 (84.6) | <0.001 |
| No | 29 (100) | 2 (15.4) | <0.001 |
| Current treatmenta (%) | |||
| 5ASA | 27 (93.1) | 10 (77.0) | 0.138 |
| Antibiotics | 7 (24.1) | 3 (23.1) | 0.945 |
| Thiopurines | 12 (41.4) | 8 (61.5) | 0.234 |
| Anti‐TNFα | 10 (34.5) | 4 (30.8) | 0.816 |
Sera and clinical details were made available from collaborators in Pavia, Italy. An intestinal stricture was present in eleven of the patients in the stricturing phenotype group, with two patients in this group having had a stricture resected previously. Unless otherwise stated, values represent total number, with percentages in brackets.
NSCD, non‐stricturing Crohn's disease; SCD, stricturing Crohn's disease; M, male; F, female; IQR, interquartile range; CDAI, Crohn's disease activity index; 5ASA, 5‐aminosalicylic acid.
a
Treatment was either current or within the previous 3 months of sample collection.